Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab Effector Mechanisms in Multiple Myeloma
NCT02419118Phase 3Completed
- Sponsor
- Vejle Hospital
- Start
- Jan 2015
- Primary completion
- Oct 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of daratumumab in multiple myeloma (MM), sponsored by Vejle Hospital. Started Jan 2015; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02419118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02419118.